148 related articles for article (PubMed ID: 31556206)
1. Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A.
Diego VP; Luu BW; Hofmann M; Dinh LV; Almeida M; Powell JS; Rajalingam R; Peralta JM; Kumar S; Curran JE; Sauna ZE; Kellerman R; Park Y; Key NS; Escobar MA; Huynh H; Verhagen AM; Williams-Blangero S; Lehmann PV; Maraskovsky E; Blangero J; Howard TE
J Thromb Haemost; 2020 Jan; 18(1):201-216. PubMed ID: 31556206
[TBL] [Abstract][Full Text] [Related]
2. Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.
Jankowski W; Park Y; McGill J; Maraskovsky E; Hofmann M; Diego VP; Luu BW; Howard TE; Kellerman R; Key NS; Sauna ZE
Blood Adv; 2019 May; 3(9):1429-1440. PubMed ID: 31053570
[TBL] [Abstract][Full Text] [Related]
3. Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits.
Schiavoni M; Napolitano M; Giuffrida G; Coluccia A; Siragusa S; Calafiore V; Lassandro G; Giordano P
Front Med (Lausanne); 2019; 6():261. PubMed ID: 31850352
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3.
Bauer A; Friberg-Hietala S; Smania G; Wolfsegger M
J Blood Med; 2023; 14():399-411. PubMed ID: 37332615
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach.
Winterling K; Martin WD; De Groot AS; Daufenbach J; Kistner S; Schüttrumpf J
J Thromb Haemost; 2021 Sep; 19(9):2161-2170. PubMed ID: 34060724
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
Grancha S; Ortiz AM; Marañón C; Hampel K; Moret A; Zimmermann B; Jorquera JI; Aznar JA
Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
[TBL] [Abstract][Full Text] [Related]
7. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
[TBL] [Abstract][Full Text] [Related]
8. An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study).
Lissitchkov T; Klukowska A; Buevich E; Maltceva I; Auerswald G; Stasyshyn O; Seifert W; Rogosch T
J Blood Med; 2020; 11():345-356. PubMed ID: 33117020
[TBL] [Abstract][Full Text] [Related]
9. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
10. Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model.
Wu J; Zhang H; Lian T; Ding Y; Song C; Li D; Wu L; Lei T; Liang H
Biochem Biophys Res Commun; 2023 Jan; 640():80-87. PubMed ID: 36502635
[TBL] [Abstract][Full Text] [Related]
11. HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII.
van Haren SD; Herczenik E; ten Brinke A; Mertens K; Voorberg J; Meijer AB
Mol Cell Proteomics; 2011 Jun; 10(6):M110.002246. PubMed ID: 21467215
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
[TBL] [Abstract][Full Text] [Related]
13. Comparative profiling of HLA-DR and HLA-DQ associated factor VIII peptides presented by monocyte-derived dendritic cells.
Peyron I; Hartholt RB; Pedró-Cos L; van Alphen F; Brinke AT; Lardy N; Meijer AB; Voorberg J
Haematologica; 2018 Jan; 103(1):172-178. PubMed ID: 29025906
[TBL] [Abstract][Full Text] [Related]
14. Switch to pdVWF:pdFVIII concentrate for prophylaxis in a paediatric patient with Type 3 von Willebrand disease: a case report.
Berger C; Thouvenin S; Montmartin A; Noyel P; Legendre C; Tardy-Poncet B
Hematology; 2023 Dec; 28(1):2186332. PubMed ID: 36892261
[TBL] [Abstract][Full Text] [Related]
15. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
Johnston A
Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
[TBL] [Abstract][Full Text] [Related]
16. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
Qadura M; Waters B; Burnett E; Chegeni R; Bradshaw S; Hough C; Othman M; Lillicrap D
Blood; 2009 Jul; 114(4):871-80. PubMed ID: 19411636
[TBL] [Abstract][Full Text] [Related]
17. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
18. International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories.
St Ledger K; Feussner A; Kalina U; Horn C; Metzner HJ; Bensen-Kennedy D; Blackman N; Veldman A; Stowers A; Friedman KD
J Thromb Haemost; 2018 Mar; 16(3):555-564. PubMed ID: 29274194
[TBL] [Abstract][Full Text] [Related]
19. Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
Delignat S; Peyron I; El Ghazaly M; V Kaveri S; Rohde J; Mueller F; Lacroix-Desmazes S
Cell Immunol; 2018 Sep; 331():22-29. PubMed ID: 29751951
[TBL] [Abstract][Full Text] [Related]
20. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
